Summary
The global Exenatide Market is expected to witness a CAGR of xx% over the forecast period 2020-2026 and is expected to reach US$ xx million in 2026, from US$ xx million in 2019.
Exenatide is a drug used to treat type II diabetes. It works to reduce blood sugar levels in diabetes and these supplements are able to lose weight and have a healthier metabolic system as well. Exenatide is a natural herb that is taken by people who are experiencing obesity or who have diabetes, as well as those who want to lose extra pounds and feel better about themselves and their body. It uses the body's own appetite suppressant properties to speed up metabolism and produce a large amount of glucose so that person will feel full so that won't be hungry all the time. Exenatide also stimulates the intestines to produce more glucagon, which will help to absorb the nutrients in food much faster.
The growing prevalence of type 2 diabetes is a key factor fueling the growth of the exenatide. According to the Centers for Disease Control and Prevention, more than 34 million Americans have diabetes (about 1 in 10), and approximately 90-95% of them have type 2 diabetes. Type 2 diabetes most often develops in people over age 45, but more and more children, teens, and young adults are also developing it. The rise in global healthcare spending by the government is again driving the growth of the exenatide. Increasing rates of obesity around the globe are again fueling the growth of the exenatide. According to the U.S. Department of Health & Human Services, the prevalence of obesity was 42.4% in 2017~2018.
However, severe side-effects associated with the consumption of exenatide is expected to hinder the growth over the forecast period.
North America is projected to gain significant growth over the forecast period and this is attributed to the high presence of the geriatric population which is increasing the prevalence of diabetes in the region. According to The U.S. Census Bureau, the 65-and-older population grew by over a third (34.2% or 13,787,044) during the past decade, and by 3.2% (1,688,924) from 2018 to 2019.
Key Developments:
- In October 2017, AstraZeneca announced that the US Food and Drug Administration (FDA) has approved Bydureon BCise (exenatide extended-release) injectable suspension, a new formulation of Bydureon in an improved once-weekly, single-dose autoinjector device for adults with type-2 diabetes
- In April 2018, Astra Zeneca has announced the FDA approved an expanded indication for the GLP-1 receptor agonist exenatide extended, it can be used as an add-on therapy with basal insulin in people with poorly controlled type 2 diabetes
The Exenatide Market report highlights product development and growth strategies such as merger and acquisition adopted by market players along with SWOT Analysis, PEST and Porter’s Five Forces analyses of the Exenatide Market, which highlight the strengths, weaknesses, opportunities, and commination of key companies. Moreover, the report offers two distinct market forecasts, one from the perspective of the producer and another from that of the consumer.
The various contributors involved in the value chain of the product include manufacturers, suppliers, distributors, intermediaries, and customers.
The Key Manufacturers covered in this Report:-
By the Product Type, the market is primarily segmented into:
- Extended-release injectable suspension
- Fast release injectable suspension
By Applications, the market is segmented into:
The Report covers the following Regions:
- North America
- United States
- Canada
- Mexico
- Asia Pacific
- China
- Japan
- South Korea
- India
- Australia
- Indonesia
- Thailand
- Malaysia
- Philippines
- Vietnam
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Central & South America
- Middle East & Africa
- Turkey
- GCC Countries
- Egypt
- South Africa
Objective of the Exenatide Market Report:
- To assess the size of the market by value and volume
- Analyze the Exenatide Market in terms of regions and major countries
- Highlight recent developments and trends in the market
- Offer perceptive data regarding major market players in terms of key developments, strategies, and product portfolio
- Determine share of the Exenatide Market in terms of various segments such as by product type, application, and end-user
- Offer accurate projection of the market for the forecast period using state-of –the-art tools and the current primary and secondary research approaches
- Discuss major factors that impact growth of the Exenatide Market
The Exenatide Market engages the readers with all pivotal approaches to understand their position in the industry based on revenue or sales growth. The report efficiently evaluates the Exenatide Market from various dimensions to deliver an end-product that is informative, elaborate, and accurate and includes detailed market segmentation, regional analysis, and competition in the market. The information in the report is backed by annual company reports, financial reports, press releases, regulatory databases, government documents, and statistical databases.
For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Key Stakeholders:
- Material suppliers/wholesalers
- Market Distributors/traders
- Regulatory bodies
- Research organizations, and consulting firms
- Commercial research & developments (R&D)
- Trade associations and industry bodies
- Importers and exporters
- End-use industries
Available Customizations:
Custom research is one of the most crucial components of the business strategy that helps an organization gain insight into specific business sector, aligned with its specific area of interest. Thus, SMI offers more accurate, pragmatic, and actionable information specifically tailored to suit your business needs.
Request Discount 
Inquire Before Buy
